• Mashup Score: 0
    Updates on the use of molecular monitoring to detect MRD in AML - 7 month(s) ago

    Laura Dillon, PhD, FACMG, National Institutes of Health, Bethesda, MD, talks on the use of molecular monitoring in acute myeloid leukemia (AML), commenting on efforts to translate next-generation sequencing (NGS) measurable residual disease (MRD) testing to the clinic. Dr Dillon also discusses aims to standardize MRD testing in this disease setting and highlights ongoing trials investigating MRD-directed interventions. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      It was a pleasure to speak with @LauraWDillon (@nih_nhlbi) at #SOHO23, who shared some insights into the use of molecular monitoring in AML & highlighted the importance of standardizing MRD testing in this disease: 🎥 https://t.co/apk6ZRGQ8v #AMLsm #LeuSM #HemOnc

  • Mashup Score: 0
    The VJSessions | VJHemOnc - 7 month(s) ago

    Roundtable discussions with leading experts in hematological oncology

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Did you know we have a VJHemOnc sessions page where you can explore exclusive roundtable discussions with leading experts in all areas of #hemonc? Check it out here: 👉 https://t.co/M0NfigPUP7 👈 #AMLsm #LeuSM #LymSM #MMsm #MPNsm #ImmunoOnc #MDSsm https://t.co/1bpkezhYJt

  • Mashup Score: 0
    Menin inhibitors for the treatment of AML: insights into the COVALENT-101 trial - 8 month(s) ago

    Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the Phase I COVALENT-101 study (NCT05153330), which is investigating a novel covalent menin inhibitor (BMF-219) in patients with acute myeloid leukemia (AML). Dr Ravandi also highlights other studies which have demonstrated positive outcomes with the use of menin inhibitors in patients with specific subsets of AML. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #SOHO23 | @fravandi1 of @MDAndersonNews discusses the COVALENT-101 trial, which is investigating BMF-219, a novel covalent menin inhibitor, in patients with AML: 👉 https://t.co/DSM7IxD8lI #LeuSM #AMLsm #HemOnc

  • Mashup Score: 0
    Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 | Vincerx Pharma - 8 month(s) ago

    Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL PALO ALTO, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through

    Source: investors.vincerx.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🚨 NEWS 🚨 First patient dosed in a phase I study of VIP943, a novel CD123 antibody-drug conjugate, to assess the safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in patients with R/R AML, MDS, or B-cell ALL. https://t.co/ptucEyk7lz. #AMLsm #leusm #MedNews https://t.co/XmDlyf0uVw

  • Mashup Score: 4
    VJHemOnc – The video journal of hematological oncology - 8 month(s) ago

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Source: www.vjhemonc.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of sanamloghavi
      sanamloghavi

      RT @VJHemOnc: What's new in the WHO and ICC classifications of AML? @sanamloghavi just gave us a great summary! 👉https://t.co/XFFSSiEpVJ👈…

    • Profile photo of VJHemOnc
      VJHemOnc

      It's always great catching up with Valeria Santini! Stay tuned for everything #MDS 👉https://t.co/Jvj1Z7sRDR👈 @UNI_FIRENZE @SocietyofHemOnc #SOHO2023 #SOHO23 #MyelodysplasticSyndromes #MDSsm #HemOnc https://t.co/C3vRPxB2I3

    • Profile photo of VJHemOnc
      VJHemOnc

      What's new in the WHO and ICC classifications of AML? @sanamloghavi just gave us a great summary! 👉https://t.co/XFFSSiEpVJ👈 @MDAndersonNews @SocietyofHemOnc #SOHO2023 #SOHO23 #Leukemia #AMLsm #LEUsm #MDSsm #HemOnc https://t.co/gjGgkNVvRN

  • Mashup Score: 0
    VJHemOnc – The video journal of hematological oncology - 8 month(s) ago

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      It’s the first day of #SOHO2023 and we’re already having a wonderful time! Exciting talks in #ALLsm, #MDSsm, #AMLsm & more today – look out for our interviews with speakers on https://t.co/O9p0vDBrzw! @SocietyofHemOnc #LeuSM #LymSM https://t.co/Y0noMhjbcr

Load More